RxDoctor Payments Data

Madelaine Fontenot, MD

Internal Medicine · Broussard, LANPI 1326542556

Payments from drug & device makers

$930in general payments, 2019–2025

Across 49 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$193
  • Exact Sciences$170
  • Pfizer$166
  • Novartis$82
  • AbbVie$75
  • Lilly USA, LLC$74
  • plus $170 from 6 others

What the payments were for

  • Food & beverage$930100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$930 in reported general payments places this provider in the 60th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$45,890
Medicare patients
130
Services billed
616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin51$63,099
MounjaroTirzepatide43$48,161
OzempicSemaglutide35$38,646
TrulicityDulaglutide31$32,102
VraylarCariprazine Hcl16$25,804
Synjardy XrEmpagliflozin/Metformin Hcl18$20,681
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$16,008
FarxigaDapagliflozin Propanediol11$14,283
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$14,238
Repatha SureclickEvolocumab12$11,321
LinzessLinaclotide17$11,134
MyrbetriqMirabegron21$9,256
Icosapent Ethyl14$4,602
Omega-3 Acid Ethyl Esters16$2,544
Rosuvastatin Calcium162$2,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$17$83,78069 claims
Lilly USA, LLCMounjaro, Trulicity$74$80,26374 claims
Novo NordiskOzempic$193$38,64635 claims
AbbVieVraylar, Linzess$75$36,93833 claims
AstraZenecaFarxiga, Breztri Aerosphere$32$28,52126 claims
GSKTrelegy Ellipta$22$16,00819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Broussard

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →